Etanercept - genetically engineered compound for back pain - falls short: study

April 16, 2012

Despite the great promise that injecting a new type of anti-inflammatory pain medicine into the spine could relieve the severe leg and lower back pain of sciatica, a Johns Hopkins-led study has found that the current standard of care with steroid injections still does better.

Etanercept, sold by the brand-name Enbrel, is a genetically engineered small-protein drug known as a inhibitor (TNF). Currently, it is used to treat and other autoimmune disorders in which the immune system attacks healthy tissue causing pain, swelling and damage. The drug blocks TNF, a naturally produced substance that causes inflammation.

Although steroids combat inflammation generally, TNF inhibitors specifically target the inflammatory molecules causing sciatica and other pain conditions, and keep them from binding to receptors in the , potentially preventing the pain altogether.

A team led by Steven P. Cohen, M.D., an associate professor of anesthesiology and at the Johns Hopkins University School of Medicine, conducted a blinded, placebo-controlled study, providing epidural injections of either 60 milligrams of a steroid, 4 milligrams of , or 2 milliliters of saline to 84 adult patients with sciatica. One month after the second of two injections, the patients on steroids reported less pain and less disability than those in the other two groups. The study is published in the April 17 issue of the .

Cohen said studies with etanercept grew out of efforts to prevent or limit the pain that commonly comes from a herniated disc pressing on a in the lower back or neck. Steroids work, he said, but they are not without drawbacks, including mixed and only temporary results in relieving pain, and the potential for catastrophic complications. Pain experts have long been working to try to find an alternative treatment that is safe and reliable, he notes.

"People are desperate for a safer, more effective drug," Cohen says. "This new treatment shows a lot of promise, but at least in the doses we gave it — the dose known to be safe — steroids still work better. And in those lower doses, etanercept may not be the drug everyone's hoping it is. There's still a lot more work to be done."

Cohen says a study published last month found that patients who received more than twice as much etanercept as was used in his study felt better than those who got steroids one and two weeks after their injections, but not four weeks out. The dose of etanercept administered by Cohen's team — 4 milligrams — was deemed to be the optimum dose found to be both safe and effective in a pilot study done by Cohen and colleagues in patients and animals.

The idea behind administering an epidural injection for sciatica is to bathe the spinal nerve roots directly in a medication designed to reduce inflammation — and pain — in order to give the body time to heal itself, Cohen says. This allows for better relief at lower doses and, in turn, fewer side effects than when the medications are given by mouth or intravenously.

The new study found that more patients treated with epidural steroids (75 percent) reported 50 percent or greater leg pain relief and felt better overall after one month compared to those who received saline (50 percent) or etanercept (42 percent). On a pain scale of 0 to 10, with 10 denoting the worst pain, those who received steroids reported, at one month, an average pain score of 2.1 compared with 3.6 in the etanercept group and 3.8 in the group injected with saline. Those in the steroid group also reported lower levels of disability (21 percent) than those in the saline group (29 percent) or etanercept group (38 percent).

After six months, however, slightly more patients in the saline (40 percent) and etanercept (38 percent) groups had a positive outcome than those in the steroid group (29 percent).

"The effect of the steroids didn't last," Cohen says, "affirming the fact that steroids work, but not for very long."

Cohen says research now needs to be done to test the safety and effectiveness of higher doses of etanercept and other drugs that block the inflammatory molecules responsible for pain.

Explore further: Costly diagnostic MRI tests unnecessary for many back pain patients

Related Stories

Costly diagnostic MRI tests unnecessary for many back pain patients

December 16, 2011
(Medical Xpress) -- Johns Hopkins-led research suggests that routine MRI imaging does nothing to improve the treatment of patients who need injections of steroids into their spinal columns to relieve pain. Moreover, MRI plays ...

Etanercept shows promise for treating dermatomyositis

June 17, 2011
A multicenter pilot study of etanercept for treatment of dermatomyositis found no major safety concerns and many patients treated with the drug were successfully weaned from steroid therapy. These results are encouraging, ...

Biomarker may signal whether common back pain treatment will work, doctor finds

August 11, 2011
A new study from researchers at the Stanford University School of Medicine has identified a unique protein complex that can be used to predict whether an epidural steroid injection will help relieve pain caused by a herniated ...

Recommended for you

Study reveals key molecular link in major cell growth pathway

October 19, 2017
A team of scientists led by Whitehead Institute has uncovered a surprising molecular link that connects how cells regulate growth with how they sense and make available the nutrients required for growth. Their work, which ...

Engineered protein treatment found to reduce obesity in mice, rats and primates

October 19, 2017
(Medical Xpress)—A team of researchers with pharmaceutical company Amgen Inc. report that an engineered version of a protein naturally found in the body caused test mice, rats and cynomolgus monkeys to lose weight. In their ...

New procedure enables cultivation of human brain sections in the petri dish

October 19, 2017
Researchers at the University of Tübingen have become the first to keep human brain tissue alive outside the body for several weeks. The researchers, headed by Dr. Niklas Schwarz, Dr. Henner Koch and Dr. Thomas Wuttke at ...

Cancer drug found to offer promising results in treating sepsis in test mice

October 19, 2017
(Medical Xpress)—A combined team of researchers from China and the U.S. has found that a drug commonly used to treat lung cancer in humans offers a degree of protection against sepsis in test mice. In their paper published ...

Tracing cell death pathway points to drug targets for brain damage, kidney injury, asthma

October 19, 2017
University of Pittsburgh scientists are unlocking the complexities of a recently discovered cell death process that plays a key role in health and disease, and new findings link their discovery to asthma, kidney injury and ...

Inflammation trains the skin to heal faster

October 18, 2017
Scars may fade, but the skin remembers. New research from The Rockefeller University reveals that wounds or other harmful, inflammation-provoking experiences impart long-lasting memories to stem cells residing in the skin, ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.